- Male or female patient of age 2 years or older.
- High-risk patients with proven, probable or possible invasive fungal infection (IFI)
according to the EORTC/MSG criteria.
- Patients indicated for secondary prophylaxis of invasive aspergillosis.
- Patients with known hypersensitivity to voriconazole or to any of the excipients.
- Patients with contraindicated concomitant medications according to the SmPC.
- Children less than 2 years of age.
- Pregnancy and lactation.